KPC Pharmaceuticals,Inc. (SHA:600422)

China flag China · Delayed Price · Currency is CNY
12.14
-0.01 (-0.08%)
Mar 10, 2026, 2:04 PM CST
-29.58%
Market Cap 9.20B
Revenue (ttm) 6.58B
Net Income (ttm) 349.94M
Shares Out 756.98M
EPS (ttm) 0.46
PE Ratio 26.41
Forward PE 13.93
Dividend 0.30 (2.47%)
Ex-Dividend Date Jul 30, 2025
Volume 3,598,100
Average Volume 7,275,539
Open 12.19
Previous Close 12.15
Day's Range 12.11 - 12.20
52-Week Range 11.82 - 18.64
Beta 0.04
RSI 43.06
Earnings Date Mar 20, 2026

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs and natural drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, artemether, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotics, immunosuppressive, oral products, injections and others. The company’s brands such as Luotai, Tianxuanqing, Artemedine, Artem and Arco. It markets art... [Read more]

Sector Healthcare
Founded 1951
Employees 5,275
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600422
Full Company Profile

Financial Performance

In 2025, KPC Pharmaceuticals,Inc.'s revenue was 6.58 billion, a decrease of -21.72% compared to the previous year's 8.40 billion. Earnings were 349.94 million, a decrease of -46.00%.

Financial Statements

News

There is no news available yet.